FOXP3 and neoplasm: In line, therapeutic application of the agonist anti-GITR monoclonal antibody DTA-1 in B16F10 melanoma-bearing mice induced regression of tumors accompanied by decreased accumulation of intra-tumor Treg cells due both to loss of Foxp3 expression and impaired infiltration (211).